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Abstract
Background: Chronic hepatitis B virus (HBV) infection is complicated by cirrhosis and liver cancer. In Thailand,
6-7 % of adults are chronically infected with HBV. The risk of mother-to-child transmission (MTCT) of HBV has been
estimated to be about 12 % when mothers have a high hepatitis B viral load, even if infants receive passive-active
prophylaxis with HBV immunoglobulin (HBIg) and initiate the hepatitis B vaccine series at birth. We designed a
study to assess the efficacy and safety of a short course of maternal tenofovir disoproxil fumarate (TDF) among
women with a marker of high viral load for the prevention of MTCT of HBV.
Methods: The study is a phase III, multicenter (17 sites in Thailand), placebo-controlled, double-blind, randomized
1:1, two-arm clinical trial of TDF 300 mg once daily versus placebo among pregnant women from 28 weeks’
gestation through 2-month post-partum. All infants receive HBIg at birth, and a hepatitis B (HB) vaccination
series according to Thai guidelines: birth, and age 1, 2, 4 and 6 months. Participant women at study entry
must be age ≥18 years, hepatitis B surface antigen (HBsAg) and e-antigen (HBeAg) positive, have alanine
aminotransferase (ALT) level < 30 IU/L at screening (confirmed < 60 IU/L pre-entry), negative hepatitis C serology,
creatinine clearance >50 mL/min, and no history of anti-HBV antiviral treatment.
The target sample size of 328 mother/infant pairs assumed 156 evaluable cases per arm to detect a ≥9 % difference in
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MTCT transmission (3 % experimental arm versus 12 % placebo arm) with 90 % power. Mothers and infants are
followed until 12 months after delivery. The primary infant endpoint is detection of HBsAg, confirmed by detection
of HBV DNA at six months of age. Secondary endpoints are maternal and infant adverse events, acute exacerbations
of maternal hepatitis B disease (ALT >300 IU/L, defined as a “flare”) following discontinuation of study treatment,
infant HBV infection status and growth up to 12 months of age.
Discussion: The results of this randomized trial will clarify the efficacy and safety of a short course of antiviral
treatment to prevent mother-to-child transmission of HBV and inform international guidelines.
Trial registration: ClinicalTrials.gov Identifier NCT01745822.
Keywords: Hepatitis B, Hepatitis B surface antigen, Hepatitis B e antigen, Pregnancy, Mother-to-child transmission,
Thailand
Background
Chronic hepatitis B virus (HBV) infection affects an esti-
mated 240 million persons worldwide, is complicated by
cirrhosis of the liver and hepatocellular carcinoma, and
causes 650,000 deaths annually [1]. HBV is most infec-
tious in persons with high-level viremia (HBV load) or
positive HBeAg, a marker of high-level viral replication.
In countries with a high prevalence (>8 %) of HBsAg-
positive persons, and before the implementation of uni-
versal immunization programs, most HBV infections
were the result of early childhood household transmis-
sion or maternal-to-child transmission (MTCT). Com-
pared to other age groups, infants have the highest rate
(about 90 %) of HBV infection progressing to chronic
HBV infection. MTCT is thought to occur primarily
during birth/delivery, but the timing and predominant
route of transmission is poorly understood.
Efficient HB vaccines have been available since the
early 1980s. The World Health Organization (WHO)
recommends universal infant immunization, regardless
of maternal HBV infection status, starting at birth. This
intervention has dramatically reduced the prevalence of
HBV infection in children wherever it has been imple-
mented. For infants born to HBV-infected mothers,
concurrent administration of HB immunoglobulin
(HBIg) to the neonate as soon as possible after birth for
added passive prophylaxis incrementally reduces the risk
of infection [2]. However, studies have reported that 8 %
to 12 % of infants born to mothers with high-level
viremia are infected despite prophylaxis with passive
(HBIg) and active (HB vaccine) immunization starting
at birth [3–5]. It is possible that in utero transmis-
sions cannot be prevented by interventions initiated
after birth. Additionally, HBV escape mutants to HB
vaccine- or HBIg- may be responsible for some trans-
missions [6, 7].
Studies have suggested that antivirals inhibiting HBV
replication such as lamivudine, tenofovir disoproxil fu-
marate (TDF), and telbivudine, prescribed to pregnant
women with high HBV loads at the end of pregnancy
and during the early postpartum period can reduce the
risk of MTCT [3, 4, 8]. This scientific evidence has been
weakened by methodological shortcomings in the studies
conducted to date. A recent meta-analysis and review
concluded that “most of the data [were] derived from
cohort studies, which are subject to significant biases,
especially selection bias,” and stressed the “absence of
studies warranting high confidence” and “a paucity of
randomized clinical trials” [9]. This led the American
Association for the Study of Liver Diseases not to rec-
ommend but rather “suggest antiviral therapy to reduce
the risk of perinatal transmission of hepatitis B in
HBsAg-positive pregnant women with an HBV DNA
level >200,000 IU/mL”, rating the Quality/Certainty of
Evidence as “Low” and the Strength of Recommendation
as “Conditional” [10]. Similarly, in 2015, the first WHO
Hepatitis Guidelines did not recommend this approach
for the sole purpose of preventing MTCT of HBV (qual-
ity of evidence rated as “Very low”), even though some
“countries in Asia have adopted a policy of treating
highly viremic pregnant mothers with lamivudine, telbi-
vudine or tenofovir” [1]. Moreover, the safety of the
approach has not been fully assessed, specifically the risk
of hepatic disease exacerbation (flare) following postpar-
tum discontinuation of antiviral treatment.
The protocol described here was designed to address
essential questions about the efficacy and safety of pro-
viding antiviral therapy to pregnant women who have
markers of high HBV load to prevent MTCT of HBV.
Indeed recent guidelines and reviews still stress the need
for well conducted randomized clinical trials with suffi-
cient sample size [1, 9, 10]. This study is being
conducted in Thailand where antiviral treatment of
pregnant women has not been implemented.
We hypothesize that a short course of TDF compared
to placebo will reduce the risk of MTCT of HBV among
HBeAg positive women, −-likely through a decrease in
HBV load and, possibly, through a prophylactic effect in
the fetus in combination with passive-active prophylaxis
at birth in the neonate–, and that only clinically
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insignificant maternal flares will occur with postpartum
antiviral discontinuation.
Methods
This is a phase III, multicenter, placebo-controlled,
double-blind, randomized (1:1), two parallel arm clin-
ical trial conducted in 17 public hospitals in Thailand
(see Fig. 1). The list of locations is available at Clini-
calTrials.gov Identifier NCT01745822. The primary
objective is to assess the efficacy of TDF for the
prevention of MTCT of HBV at 6 months of age. Im-
portant secondary objectives are to assess the risk of
postpartum hepatic disease exacerbation after antiviral
discontinuation, and infant growth through 12 months
of age as part of the safety assessments.
Pregnant women are tested for the presence of HBsAg
at their first antenatal care visit as standard of care in
Thailand. At each site, all pregnant women aged 18 years
or older with a positive HBsAg test were informed about
the study and invited to provide their informed consent
for participation.




 At least 18 years of age
 Negative Human Immunodeficiency Virus serology
 Positive HBsAg and HBeAg tests
 Gestational age of 28 weeks (+ or - 10 days) as
determined by the study site obstetrician
 Alanine aminotransferase (ALT) ≤30 IU/L,
confirmed ≤60 IU/L on a subsequent
blood draw
 Pregnant woman agrees to bring her infant at the
planned study visits at a study site, until one year
after delivery and to inform the site investigator if
she plans to move to another place and not be able
to return to the clinic.
 Pregnant woman understands the need for
adequate infant immunization and agrees to the
blood draws from her infant and the need for
close follow-up to manage possible exacerbation
of hepatitis.
Exclusion Criteria:
 History of TDF treatment at any time, or any
other anti-HBV treatment during the current
pregnancy.
 Creatinine clearance <50 mL/min, calculated using
the Cockcroft-Gault formula.
 Dipstick proteinuria > 1+ (>30 mg/dL) or
normoglycemic glucosuria confirmed on two
separate occasions.
 Positive serology for Hepatitis C infection.
 Evidence of fetal anomalies incompatible with life.
 Any concomitant condition or treatment that, in
the view of the clinical site investigator, would
contraindicate participation or satisfactory follow-up
in the study.
 Concurrent participation in any other clinical trial
without written agreement of the two study teams.
At 28 weeks gestation (+/−10 days), eligible partici-
pants are enrolled and randomly assigned to receive the
study treatment (manufactured by Gilead Sciences Inc.)
of either TDF 300 mg once daily in the “TDF” experi-
mental arm or a matching placebo in the reference arm,
from 28 weeks gestation through 2-months postpartum.
Women are instructed to return to the study pharmacist
any unused study treatment and empty bottles;
Fig. 1 Study design
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adherence to treatment is assessed by self-report and
exact pill count. All infants receive passive-active
prophylaxis with HBIg at birth and HB vaccination ac-
cording to Thai guidelines: at birth, and ages 1, 2, 4 and
6 months of age. Following WHO guidelines, mothers
are encouraged to breastfeed as there is no evidence of
additional transmission during breastfeeding [11, 12].
Mothers and infants are followed until 12 months after
delivery. Maternal study visits are conducted at 28, 32,
36 weeks’ gestation, delivery, and at 1, 2, 3, 4, 6 and
12 months postpartum. For mothers with confirmed
moderate liver disease exacerbation (ALT >60 IU/L)
after discontinuation of the study treatment, specific
evaluations are conducted including bilirubin, prothrom-
bin/International Normalized Ratio, and albumin, and
plasma is stored for further retrospective evaluations.
Additional investigations are performed for case man-
agement and documentation, and reintroduction of the
double-blind study treatment is considered following a
pre-defined algorithm by the reference site internist if
high ALT levels persist. Infant visits are scheduled at
birth, 1, 2, 4, 6, 9 and 12 months of age for clinical safety
evaluation and determination of HBV status.
Serious adverse events (SAEs) that occur in either
arm, as defined by 1996 International Conference on
Harmonisation Good Clinical Practice, whether or not
considered to be related to the study treatment by
the study site investigator, are immediately reported
to the Thai Ministry of Public Health and to the
Eunice Kennedy Shriver National Institute of Child
Health & Human Development (NICHD) and Centers
for Disease Control and Prevention (CDC) program
scientists, and those related to the study treatment to
the drug manufacturer.
The primary endpoint is the detection of HBsAg that
is confirmed by detectable HBV DNA in infants at six
months of age. Secondary endpoints are infant’s HBV
infection status, defined as detection of HBsAg con-
firmed by detectable HBV DNA at or after 6 months
through 12 months of age, occurrence of maternal and
infant adverse events (SAEs and grade 3/4 signs and
symptoms in the Division of AIDS Table for Grading the
Severity of Adult and Pediatric Adverse Events, Ver-
sion 1.0, December, 2004 [13]), occurrence of flares
(ALT >300 IU/L) following discontinuation of study
treatment, and infant growth measured by weight, height
and head-circumference at 6 and 12 months of age.
Randomization, allocation concealment, and blinding
The sequentially numbered permuted blocks (of size un-
disclosed to the investigators) randomization list was
computer generated by the study statistician (who had
no further involvement in study treatment allocation)
before the study started. The list, securely transmitted to
the study pharmacist only, is used for secondary pack-
aging of study treatment, consisting of 30-tablet bottles,
into sequentially ordered packages. Stratification by site
is achieved by shipping packages of study treatment
divisible by the block size and blinding is achieved by
only identifying study treatment by the patient identifi-
cation number dictated by the sequential list. Patients,
study staff on site and at the coordination center, investi-
gators and laboratory personnel in charge of HBV
related tests are blind to the randomized assignment.
Sample size
It was calculated that a total of 312 evaluable mother-
infant pairs were needed to detect a ≥9 % difference in
HBV transmission between arms (3 % in the experimen-
tal arm versus 12 % in the placebo arm) with 90 %
power using a Fisher’s exact test and a one-sided 0.049
significance level to account for one interim efficacy ana-
lysis. This difference is equivalent to a relative reduction
of 75 % in HBV infection rate in the TDF arm. It was
planned to enroll 328 pregnant women to account for
an estimated 5 % loss to follow-up. If the infection rate
in the placebo arm is only 10 %, the study has 83.2 %
power to detect a 75 % reduction in the infection rate,
i.e., an infection rate at 2.5 % in the TDF arm. However,
if the infection rate is only 8 %, the power of detecting a
75 % reduction in the infection rate (2 % infection rate
in the placebo arm) drops to 72.6 %.
Monitoring
The composition of the Data and Safety Monitoring
Board (DSMB) adhered to the following criteria: at least
1 gastroenterologist/hepatologist, 1 pediatrician, 1 ob-
stetrician, 1 infectious diseases specialist, and 1 statisti-
cian/ epidemiologist, at least 3 of them from Thailand.
Program scientists participate as observers in open ses-
sions of DSMB calls/meetings. The study was presented
to the DSMB during a protocol initiation review before
study initiation. At annual meetings, the DSMB reviews
the conduct of the study and adverse events. One in-
terim review to monitor efficacy is planned when 50 %
of the information on the primary endpoint is available,
i.e. when 164 infants either have their 6-month HBV
status available or are off study before the 6-month visit.
A Haybittle-Peto function is employed for the group
sequential design, so that at the interim efficacy review,
the comparison of the primary endpoint is considered
significant only if p < 0.001.
Statistical analyses
For the primary objective/endpoint, the proportions of
infants with positive HBsAg, confirmed by HBV DNA,
at 6 months of age, along with their 95 % confidence
intervals, will be provided by arm based on the exact
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Binomial distribution and compared between the TDF
arm and the placebo arm based on Fisher’s exact test.
The test will be adjusted for the interim efficacy moni-
toring by considering p < 0.05 – 0.001 = 0.049 as signifi-
cant. If mothers’ baseline HBV DNA loads are
imbalanced between treatment arms, an exact logistic
regression will be conducted as a sensitivity analysis.
The primary analysis will be conducted as a complete
case analysis including infants whose 6-month endpoint
is available in their original randomized group, regard-
less of the duration of study treatment their mothers
actually received - if at least one dose was taken. A
secondary analysis will be conducted in a modified
intent to treat (mITT) population, where all random-
ized pregnant women who received at least one dose
of study treatment will be included, and infants who
are lost to follow-up before their 6 months HBV sta-
tus is available will be considered as infected. Further
sensitivity analysis may be performed, including im-
puting infants’ last available HBV infection status as
their 6 months status for those who are lost to
follow-up prior to 6 months or multiple imputations
accounting for possible reasons of loss to follow-up,
to explore the effect of loss to follow-up. A second-
ary supporting analysis will be conducted also con-
sidering as HBV infected infants with positive
HBsAg, confirmed by HBV DNA, after 6 months and
up to 12 months of age. Logistic regression, account-
ing for factors that are known to be associated with
mother-to-child HBV transmission, could also be
conducted to provide an adjusted odds ratio between
treatment arms.
For secondary objectives/endpoints, proportions of
women with severe hepatic disease exacerbation (ALT
>300 IU/L, regardless of baseline values) occurring after
study treatment discontinuation and up to 12 months
postpartum will be compared between treatment arms
by Fisher’s exact test. Proportions of women with any
adverse event (any SAE or grade 3/4 sign or symptom
defined by the Division of AIDS) from randomization
until study exit will be analyzed similarly. Poisson re-
gressions, with an offset of follow-up time will be further
conducted to model repeated occurrence of adverse
events. Adverse events in infants will be analyzed in a
similar manner. Infants’ mean weight, height and head
circumference z-scores at 6 and 12 months of age will
be compared between arms based on normal approxi-
mation and two-sample t-tests.
In exploratory analysis, the proportion of infants with
detectable 9 month HBV DNA and that of infants with
seroprotection (anti-HBs antibodies > 10 IU/L) will be
compared by treatment arm, as well as the proportions
of premature labors (birth before 37 weeks of gestational
age assessed by Ballard Score). Additional exploratory
analyses include, but are not limited to, analysis on time
to treatment discontinuation and/or study discontinu-
ation and analysis on adherence.
Quarterly conference calls involving the core protocol
team and program scientists are held to review the pro-
gress of the study and adverse events. The implementa-
tion of the study at each site is audited by a contract
research organization one to three times during the
study period, depending on the number of enrollees.
All site investigators have been trained in Good Clin-
ical Practice and Human Subjects Protection. The trial
protocol was reviewed and approved on September 3,
2012 by the Ethics Committees of the Institute for the
Development of Human Research Protections at the
Thailand’s Ministry of Public Health (reference สคม 1340/
2555), the Faculty of Associated Medical Sciences,
Chiang Mai University, on October 18, 2012 (reference
525/2555), the NICHD, and the CDC, as well as by the
ethics committees of participating sites in Thailand.
Discussion
This phase III randomized placebo-controlled double-
blind trial will assess the efficacy and safety of a short
course antiviral treatment to prevent mother-to-child
transmission of HBV. Enrollment was opened in January
2013 and accrual was completed on August 19, 2015
with no significant operational issues. The data collec-
tion for the primary endpoint is scheduled to be com-
pleted in August 2016. Primary efficacy results are
expected soon afterwards. The efficacy and safety study
results will help clarify whether this strategy can play a
significant role in the prevention of mother-to-child
HBV transmission in highly viremic women.
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